News
TOP 100 STARTUP AWARD 2016: on 14th September, Amal Therapeutics reached the top 10
Each year, startup.ch launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung and PME Magazine. From over 100.000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts. On Wednesday 14th September 2016, Amal Therapeutics reached the top10, and was elected at the rank number 8 by […]
Amal Therapeutics Wins 2d prize 2016 at Global Healthcare Innovation Academy (GHIA), Calgary
Amongst several applications within the four partner sites, 14 candidates have been shortlisted for the 2016 Global Healthcare Innovation Academy in Calgary. Amal Therapeutics represented by Jean-François Mayol, was selected in the top 6 innovations by the Grand Jury comprised of international and local experts in science, innovation, healthcare, business, IP and marketing. Amal Therapeutics […]
Amal Therapeutics to publish R&D outcomes in Molecular Therapy
Geneva, Switzerland, July 5, 2016 – Amal Therapeutics announced today that part of its recent research findings about the enhancement of anti-tumor immune responses through optimized combination of adjuvant and cellpenetrating peptide based-vaccines, is available on-line on the Molecular Therapy website on Tuesday July 5, 2016. View PDF
Amal Therapeutics SA announces the appointment of Dr. Jean-Yves Bonnefoy as member of the Scientific Advisory Board
Geneva, Switzerland, April 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced the appointment of Jean-Yves Bonnefoy as new Scientific Advisory Board (SAB) member. Dr. Bonnefoy will bring over 20 years experience in Biotechnology company leadership and therapeutic cancer vaccine development. View PDF
Amal Therapeutics receives CTI grant to evaluate immunotherapy combination treatments
Geneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments. View PDF